07:00 , Apr 13, 2015 |  BC Week In Review  |  Company News

Alere Inc, Qiagen deal

Qiagen purchased circulating tumor cell (CTC) detection technology and two diagnostics -- AdnaTest BreastCancer and AdnaTest Prostate Cancer -- from Alere’s AdnaGen GmbH subsidiary. AdnaTest BreastCancer is a breast cancer diagnostic that uses RT-PCR...
07:00 , Apr 13, 2015 |  BC Week In Review  |  Company News

Qiagen N.V, Tokai deal

Qiagen and Tokai partnered to co-develop a liquid biopsy circulating tumor cells (CTCs) companion diagnostic. The diagnostic will be used with Tokai’s galeterone, a selective androgen receptor modulator (SARM) and cytochrome P450 17 alpha-hydroxylase/C17,20...
07:00 , Sep 17, 2012 |  BioCentury  |  Emerging Company Profile

KellBenx: Capturing fetal cells

KellBenx Inc. is developing prenatal diagnostics that it says will capture larger amounts of intact fetal DNA from a maternal blood sample, allowing the biotech to diagnose a wider range of genetic abnormalities than marketed...
08:00 , Nov 22, 2010 |  BC Week In Review  |  Company News

OncoVista deal

OncoVista will receive up to $65 million in cash and milestones as part of Alere Holdings Bermuda Ltd.'s acquisition of OncoVista's majority-held AdnaGen AG subsidiary. OncoVista has a 78% stake in the subsidiary. Alere...
07:00 , Jun 28, 2010 |  BC Week In Review  |  Company News

KellBenx, OncoVista deal

OncoVista's AdnaGen AG subsidiary granted KellBenx an option to license exclusive, worldwide rights to undisclosed mAbs against fetal erythroid cells for use in developing prenatal diagnostics. Kellbenx is currently developing non-invasive prenatal diagnostics with...
08:00 , Feb 1, 2010 |  BC Week In Review  |  Company News

OncoVista, TATAA Molecular Diagnostics deal

OncoVista's AdnaGen AG subsidiary granted TATAA exclusive rights to use its AdnaTest BreastCancer assay in the COHERTA project. The diagnostic uses RT-PCR to detect biomarkers in circulating tumor cells (CTC). The COHERTA study...
08:00 , Nov 16, 2009 |  BC Week In Review  |  Clinical News

AdnaTest BreastCancer: Post-marketing study data

Researchers at University Hospital Essen and University Hospital of Tuebingen reported that AdnaTest BreastCancer detected an EMT marker and ALDH1 in 62% and 69%, respectively, of 69 blood samples that were positive for CTCs from...
07:00 , Aug 3, 2009 |  BC Week In Review  |  Clinical News

AdnaTest BreastCancer update

This month, researchers will begin a laboratory study in samples from patients who have completed neoadjuvant and local therapy to compare AdnaTest BreastCancer diagnostic vs. CellSearch Circulating Tumor Cell Kit from Veridex LLC, a...
07:00 , Jun 23, 2008 |  BC Week In Review  |  Company News

AdnaGen, OncoVista deal

OncoVista increased its stake in AdnaGen to over 95% from 85% for an undisclosed amount. OncoVista said the acquisition will allow it to realize revenues from sales and to control the use of AdnaGen’s AdnaTest...
07:00 , Apr 14, 2008 |  BC Week In Review  |  Company News

AdnaGen management update

AdnaGen AG, Langenhagen, Germany   Business: Diagnostic, Cancer   Hired: Wolfram Rodatz as CEO, formerly general manager at Digilab BioVisioN GmbH   ...